Target-Site Investigation for the Plasma Prolactin Response: Mechanism-Based Pharmacokinetic-Pharmacodynamic Analysis of Risperidone and Paliperidone in the Rat
Open Access
- 1 February 2017
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 45 (2) , 152-159
Abstract
To understand the drivers in the biological system response to dopamine D2 receptor antagonists, a mechanistic semiphysiologically based (PB) pharmacokinetic-pharmacodymanic (PKPD) model was developed to describe prolactin responses to risperidone (RIS) and its active metabolite paliperidone (PAL). We performed a microdialysis study in rats to obtain detailed plasma, brain extracellular fluid (ECF), and cerebrospinal fluid (CSF) concentrations of PAL and RIS. To assess the impact of P-glycoprotein (P-gp) functioning on brain distribution, we performed experiments in the absence or presence of the P-gp inhibitor tariquidar (TQD). PK and PKPD modeling was performed by nonlinear mixed-effect modeling. Plasma, brain ECF, and CSF PK values of RIS and PAL were well described by a 12-compartmental semi-PBPK model, including metabolic conversion of RIS to PAL. P-gp efflux functionality was identified on brain ECF for RIS and PAL and on CSF only for PAL. In the PKPD analysis, the plasma drug concentrations were more relevant than brain ECF or CSF concentrations to explain the prolactin response; the estimated EC50 was in accordance with reports in the literature for both RIS and PAL. We conclude that for RIS and PAL, the plasma concentrations better explain the prolactin response than do brain ECF or CSF concentrations. This research shows that PKPD modeling is of high value to delineate the target site of drugs.Keywords
This publication has 28 references indexed in Scilit:
- An Evaluation of Using Rat-Derived Single-Dose Neuropharmacokinetic Parameters to Project Accurately Large Animal Unbound Brain Drug ConcentrationsDrug Metabolism and Disposition, 2012
- Species Comparison of In Vivo P-Glycoprotein-Mediated Brain Efflux Using mdr1a-Deficient Rats and MiceDrug Metabolism and Disposition, 2012
- Piraña and PCluster: A modeling environment and cluster infrastructure for NONMEMComputer Methods and Programs in Biomedicine, 2011
- Regional P-Glycoprotein Activity and Inhibition at the Human Blood–Brain Barrier as Imaged by Positron Emission TomographyClinical Pharmacology & Therapeutics, 2010
- Positron Emission Tomography Measurement of Dopamine D2Receptor Occupancy in the Pituitary and Cerebral CortexThe Journal of Clinical Psychiatry, 2010
- An Agonist–Antagonist Interaction Model for Prolactin Release Following Risperidone and Paliperidone TreatmentClinical Pharmacology & Therapeutics, 2008
- Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in miceBehavioural Brain Research, 2008
- Thyroxine (T4) transfer from CSF to choroid plexus and ventricular brain regions in rabbit: Contributory role of P-glycoprotein and organic anion transporting polypeptidesBrain Research, 2007
- P-glycoprotein interaction with risperidone and 9-OH-risperidone studiedin vitro, in knock-out mice and in drug-drug interaction experimentsHuman Psychopharmacology: Clinical and Experimental, 2005
- The Differential Effects of Atypical Antipsychotics on Prolactin Elevation Are Explained by Their Differential Blood-Brain Disposition: A Pharmacological Analysis in RatsThe Journal of Pharmacology and Experimental Therapeutics, 2002